Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 17;12(4):e01962-21. doi: 10.1128/mBio.01962-21

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Mladinich et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

PMC Copyright notice

FIG 2 — CCL5-CCR3/5 neutralization decreases ZIKV infection in hBMECs. hBMECs were infected with ZIKV (MOI of 5) and treated with isotype control or CCL5-, CCR3-, or CCR5-neutralizing antibodies (10× antibody ND50) added to supernatants once daily. (A) hBMECs were starved overnight at 3 dpi, and ZIKV NS5 was quantified by Western blot analysis and normalized to GAPDH levels. (B) ZIKV antigen-positive hBMECs were detected by anti-DENV4 hyperimmune mouse ascitic fluid (HMAF) and quantified at 3 dpi. (C) Viral titers of ZIKV-infected hBMEC supernatants were determined by a focus-forming unit (FFU) assay at 3 dpi. (D) At 9 dpi, daily neutralizing antibody-treated ZIKV-infected hBMECs were assessed for ZIKV antigen-positive hBMECs. Asterisks indicate statistical significance (*, P < 0.05; ***, P < 0.001). Experiments were performed at least 3 times with similar results.